MexBrain is a clinical-stage biotechnology company developing MEX-CD1, a superchelating polymer designed to extract toxic metals from the bloodstream using dialysis. The technology targets conditions such as Wilson's Disease and Acute Kidney Injury, aiming to reduce harmful metal levels in patients undergoing treatment.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WFounders
Product
Problem
Current treatments for metal toxicity, such as Wilson's Disease and Acute Kidney Injury (AKI), may not efficiently remove toxic metals from the bloodstream, leading to continued health complications. Existing methods can be invasive or lack the specificity needed to target and eliminate harmful metals effectively.
Solution
MexBrain is developing MEX-CD1, a superchelating polymer designed for extracorporeal removal of toxic metals from blood during dialysis. As a medical device, MEX-CD1 selectively binds to free metals like iron, copper, and lead, facilitating their extraction via a standard dialysis machine. This approach aims to reduce the burden of metal toxicity in patients with conditions like Wilson's Disease and AKI, where elevated levels of free metals contribute to disease progression. The company is currently conducting clinical trials to evaluate the safety and efficacy of MEX-CD1 in reducing free metal content in patients with acute conditions.
Target Audience
The primary target audience includes patients with Wilson's Disease, Acute Kidney Injury (AKI), and other conditions involving metal toxicity, as well as the healthcare providers who treat them, such as nephrologists and hepatologists.
Features
- Novel superchelating polymer (MEX-CD1) with high affinity for toxic metals
- Designed for use with standard dialysis equipment for extracorporeal metal extraction
- Selective binding to free metals, minimizing disruption of essential metal homeostasis
- ISO 13485 certified for design, development, manufacture, and distribution of dialysis medical devices
- Actively recruiting for pilot clinical trials (MEXWILS and MEXACLF) in Europe